^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Blenrep (belantamab mafodotin-blmf)

    i
    Other names: GSK2857916, J6M0-mcMMAF, GSK 2857916, GSK-2857916, GSK916, GSK-916, GSK 916
    Company:
    GSK, Pfizer
    Drug class:
    Microtubule inhibitor, BCMA-targeted antibody-drug conjugate
    Related drugs:
    4d
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Sep 2026 --> Sep 2027
    Trial completion date • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    10d
    Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=88, Recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Recruiting
    Enrollment open
    |
    dexamethasone • Blenrep (belantamab mafodotin-blmf) • iberdomide (CC-220)
    18d
    ALANIS: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, GlaxoSmithKline | Trial completion date: Feb 2032 --> Dec 2032 | Trial primary completion date: Aug 2027 --> Dec 2032
    Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Blenrep (belantamab mafodotin-blmf)
    24d
    DREAMM 14: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=177, Completed, GlaxoSmithKline | Active, not recruiting --> Completed
    Trial completion
    |
    Blenrep (belantamab mafodotin-blmf)
    1m
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Completed --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    1m
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Completed, PETHEMA Foundation | Not yet recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    2ms
    Tailored strategies for improved control of CAR-T cells in multiple myeloma. (PubMed, Front Immunol)
    Tyrosine-kinase inhibitor dasatinib rapidly and reversibly inhibited CAR-T activation, serving as an efficient "on/off" switch with the limitation of also inhibiting unmodified T cells...However, conditioning with fludarabine/cyclophosphamide profoundly depletes NK cells, limiting antibody-dependent CAR-T clearance in patients...In this work, we demonstrate that the BCMA-targeting ADC belantamab-mafodotin selectively eliminates BCMA co-expressing CAR-T cells without affecting unmodified T cells. These findings suggest ADCs as a potent, effector cell-independent safety mechanism for CAR-T therapies, potentially enhancing controllability and safety in future clinical applications.
    Journal
    |
    SLAMF7 (SLAM Family Member 7)
    |
    dasatinib • cyclophosphamide • fludarabine IV • Blenrep (belantamab mafodotin-blmf)
    2ms
    DREAMM-3: Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=325, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jul 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    2ms
    COSTA: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Cristiana Costa Chase, DO | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2025 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Blenrep (belantamab mafodotin-blmf)
    2ms
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=20 --> 4
    Enrollment closed • Enrollment change • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    2ms
    Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=62, Recruiting, Mayo Clinic | Trial completion date: May 2027 --> Jun 2034 | Trial primary completion date: May 2026 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    Blenrep (belantamab mafodotin-blmf)
    2ms
    DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (clinicaltrials.gov)
    P1/2, N=153, Recruiting, GlaxoSmithKline | Phase classification: P1 --> P1/2 | N=55 --> 153
    Phase classification • Enrollment change
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)